S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24

OncoCyte (OCX) Stock Forecast, Price & News

-0.10 (-9.23%)
(As of 05/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
802,918 shs
Average Volume
487,798 shs
Market Capitalization
$98.34 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OncoCyte logo

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.


See More Headlines

Industry, Sector and Symbol

Stock Exchange
Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$7.73 million
Book Value
$0.57 per share


Net Income
$-64.10 million
Net Margins
Pretax Margin




Free Float
Market Cap
$98.34 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

2.28 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte
or view top-rated stocks.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) issued its earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. OncoCyte had a negative net margin of 877.80% and a negative trailing twelve-month return on equity of 52.12%.
View OncoCyte's earnings history

What price target have analysts set for OCX?

5 brokerages have issued 12 month price targets for OncoCyte's shares. Their forecasts range from $1.40 to $6.00. On average, they anticipate OncoCyte's stock price to reach $3.90 in the next year. This suggests a possible upside of 296.3% from the stock's current price.
View analysts' price targets for OncoCyte
or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?
OncoCyte's management team includes the following people:
  • Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 62, Pay $978.35k)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Ms. Padma Sundar, Chief Commercial Officer
  • Ms. Gisela A. Paulsen, Chief Operating Officer
  • Ms. Li Yu, VP, Controller & Principal Accounting Officer
  • Dr. Ekkehard Schutz M.D., Ph.D., Chief Technology Officer
  • Mr. William Annett, Advisor (Age 68)
  • Dr. Douglas T. Ross M.D., Ph.D., Chief Science Officer
  • Mr. Robert S. Seitz, Head of Immune Oncology (Age 58)
  • Dr. Michael D. West Ph.D., Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 69)
What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.35%), Vanguard Group Inc. (4.32%), Defender Capital LLC. (2.78%), State Street Corp (1.47%), Northern Trust Corp (0.60%) and Goldman Sachs Group Inc. (0.50%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine and Ronald Asbury Andrews.
View institutional ownership trends for OncoCyte

Which institutional investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., Nisa Investment Advisors LLC, Northern Trust Corp, State Street Corp, UBS Group AG, Renaissance Technologies LLC, and California State Teachers Retirement System.
View insider buying and selling activity for OncoCyte
or view top insider-selling stocks.

Which institutional investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC., Vanguard Group Inc., Goldman Sachs Group Inc., Raymond James Financial Services Advisors Inc., DCF Advisers LLC, and Simplex Trading LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Mitchell S Levine, and Ronald Asbury Andrews.
View insider buying and selling activity for OncoCyte
or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $0.98.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $98.34 million and generates $7.73 million in revenue each year. The biotechnology company earns $-64.10 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 110 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (949) 409-7600, via email at [email protected], or via fax at 510-521-3389.

This page was last updated on 5/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.